USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
APOGEE BIOTECHNOLOGY CORPORATION
Address:
1214 Research Blvd
Suite 2014
HUMMELSTOWN, PA 17036-9196
Phone:
N/A
URL:
N/A
EIN:
125190104
DUNS:
95628348
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $3,740,165.00 11
SBIR Phase II $4,565,854.00 3
STTR Phase I $1,387,895.00 3

Award List:

NOVEL AZABICYCLOOCTANE INHIBITORS OF P-GLYCOPROTEIN

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$491,543.00
Agency:
HHS
Principal Investigator:
Abstract:
Cancer chemotherapy often provides temporary clinical improvement. However, tumor cells that survive the initial treatment often develop into cancers with multiple drug resistance (MDR). This is most often mediated by increased levels of the transport protein P-glycoprotein (PgP). A related family… More

IMPROVED ANTI-HIV THERAPY WITH P-GLYCOPROTEIN INHIBITORS

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$100,011.00
Agency:
HHS
Principal Investigator:
Abstract:
Current treatment protocols for AIDS involve combinations of nucleoside analogs and HIV protease inhibitors, but are not successful in curing the disease. The drug transport protein, P-glycoprotein (Pgp) effluxes a wide variety of drugs, including all FDA-approved protease inhibitors. A growing… More

Novel Inhibitors of Human N-Myristoyltransferase

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$492,349.00
Agency:
HHS
Principal Investigator:
Abstract:
The goal of this project is to identify and characterize novel inhibitors of human N-myristoyltransferase (NMT) that are effective as cancer therapeutic agents. Studies have shown that NMT catalyzes critical steps in the processing of several oncoproteins, and that genetic inhibition of this process… More

Novel Inhibitors of Sphingosine Kinase

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$473,108.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this program is to identify and evaluate novel inhibitors of human sphingosine kinase (SK) as anticancer therapeutic agents. We have focused on SK as a innovative molecular target for cancer therapy because of its critical role in… More

Inhibitors of Human Pal mitoyl Acyltransferase

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$647,461.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this program is to develop novel inhibitors of human palmitoyl acyltransferases (PATs) that are effective as cancer therapeutic agents. PATs represent new targets for anticancer drug development because of their pivotal roles in regulating the… More

Sphingosine Kinase Inhibitors of Diabetic Retinopathy

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$129,250.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this program is to identify and develop novel inhibitors of human sphingosine kinase (SK) that are effective as therapeutic agents. Because of its critical role in sphingolipid metabolism and angiogenesis, we have focused on SK as an… More

Sphingosine Kinase Inhibitors as Anti-IBD Agents

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$176,603.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this program is to develop novel inhibitors of human sphingosine kinase (SK) that are effective as therapeutic agents. Because of its critical role in sphingolipid metabolism, we have focused on SK as an innovative molecular target for the… More

Sphingosine Kinase Inhibitors as Anti-Arthritis Agents

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this program is to develop novel inhibitors of human sphingosine kinase (SK) that are effective for the treatment of arthritis. Sphingolipids are being increasingly recognized as key mediators of apoptosis, stress responses, cell… More

Sphingosine Kinase Inhibitors as Anti-IBD Agents

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$1,694,409.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this program is to develop novel inhibitors of human sphingosine kinase (SK) that are effective as therapeutic agents. Because of its critical role in sphingolipid metabolism, we have focused on SK as an innovative molecular target for the development… More

Anti-Atherosclerosis Agents Targeting Sphingosine Kinase

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$219,476.00
Agency:
HHS
Principal Investigator:
Lynn Maines
Abstract:
DESCRIPTION (provided by applicant): Principal Investigator/Program Director: French, Kevin J. Abstract: The long-term goal of this program is to develop inhibitors of human sphingosine kinase (SK) that are effective as therapeutic agents. Because of its critical role in sphingolipid metabolism, we… More

Sphingosine Kinase Inhibitors as Anti-Retinopathy Agents

Award Year / Program / Phase:
2007 / SBIR / Phase II
Award Amount:
$1,874,803.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of this program is to develop novel inhibitors of human sphingosine kinase (SK) that are effective as therapeutic agents for retinal and choroidal vascular diseases. Because of its critical role in sphingolipid metabolism, we have focused on SK as an… More

Sphingosine Kinase Inhibitors as Anti-Arthritis Agents

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$996,642.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Sphingolipids are being increasingly recognized as key mediators of inflammatory cascades of critical importance in multiple diseases, including rheumatoid arthritis and osteoarthritis. Most importantly, sphingosine 1-phosphate produced by sphingosine kinase… More

Optimization of dipeptide-linked benzimidazole topoisomerase 1 poisons

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$260,988.00
Agency:
HHS
Principal Investigator:
Research Institution:
MEDICAL UNIVERSITY OF SOUTH CAROLINA
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Derivatives of camptothecin (CPT) that inhibit Topoisomerase I (Top1) activity have demonstrated clinical utility in the treatment of various cancers. However, limitations in CPT pharmaceutical properties have driven th e search for new CPT-like poisons that… More

Improvement of Liver Transplantation by a Sphingosine Kinase Inhibitor

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$526,907.00
Agency:
HHS
Principal Investigator:
Research Institution:
MEDICAL UNIVERSITY OF SOUTH CAROLINA
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Severe shortages of donor organs limit the use of orthotopic liver transplantation (LT), the only proven therapy for end-stage liver diseases. Primary non-function (PNF) of liver grafts after transplantation typically r esults in recipient death or necessitates… More

Lipid Metabolism and KSHV-associated Lymphoma Pathogenesis

Award Year / Program / Phase:
2010 / STTR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Christopher H. Parsons – 843-792-3644
Research Institution:
Medical University Of South Carolina
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of cancers arising preferentially within immune compromised hosts, including patients infected with HIV. One of these cancers, a clonal B-cell malignancy known as primary effusion… More

Treatment of Inflammatory Bowel Disease with Ceramidase Inhibitors

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$316,916.00
Agency:
HHS
Principal Investigator:
Lynn W. Maines – 717-566-8635
Abstract:
DESCRIPTION (provided by applicant): The goal of this program is to develop novel inhibitors of human neutral ceramidase (ASAH2) that are effective as therapeutic agents for Inflammatory Bowel Diseases (IBDs). Sphingolipids are being increasingly recognized as key mediators of inflammation, and are… More

Mitigation of Radiation-Induced Pulmonary Fibrosis by a Sphingosine Kinase Inhibi

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$593,448.00
Agency:
HHS
Principal Investigator:
Lynn W. Maines – 717-531-4758
Abstract:
DESCRIPTION (provided by applicant): Radiation-induced production of pro-inflammatory and pro-fibrotic cytokines results in chronic and irreversible damage to the lungs. To date, no agent has demonstrated a sufficient safety profile to be utilized as a clinical drug for mitigating damage from… More